Approval · Notice of Compliance 19715 · 2017
ALEVE: Notice of Compliance 19715
Issued August 25, 2017
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 19715
- Date
- August 25, 2017
- Company
- Bayer Inc Consumer CareMississauga, Ontario, Canada
- Product type
- Nonprescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- To add a 12 hour logo to all labels
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ALEVE | 02301733 | Marketed |
| ALEVE LIQUID GELS | 02361795 | Marketed |
Medicinal ingredients
- NAPROXEN SODIUM 220 MG per TAB
- NAPROXEN SODIUM 220 MG per CAP